12:00 AM
 | 
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Endometrial Regenerative Cells: Phase I/II started

Medistem began an open-label, U.S. Phase I/II trial to evaluate 50 million, 100 million and 200 million intramuscular ERC in about 15 patients with CLI. ERCell has exclusive rights to...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >